NCT07165886View on ClinicalTrials.gov

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

243

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

August 29, 2028

Study Completion Date

August 29, 2028

Conditions

Gastroenteropancreatic Neuroendocrine Tumors

Interventions

DRUG

Sirolimus for injection (albumin bound)

Sirolimus for injection (albumin bound), ivgtt., Q2W

DRUG

Octreotide long-acting injection

SC, Q2W

DRUG

Everolimus

Oral, once a day

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT07165886 - Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter